Tirzepatide was associated with reduced CV outcomes and all-cause mortality compared to imputed placebo in patients with type 2 diabetes and established atherosclerotic CV disease.
Does tirzepatide reduce CV outcomes and all-cause mortality in participants with type 2 diabetes and established atherosclerotic CV disease?
An indirect imputed placebo analysis suggests tirzepatide reduces cardiovascular outcomes and mortality in patients with type 2 diabetes and established ASCVD.
Absolute Event Rate: 0% vs 0%
In this indirect prespecified exploratory comparison, tirzepatide compared with imputed placebo was associated with reduced CV outcomes and all-cause mortality in participants with type 2 diabetes and established atherosclerotic CV disease.
Sattar et al. (Mon,) reported a other. Tirzepatide was associated with reduced CV outcomes and all-cause mortality compared to imputed placebo in patients with type 2 diabetes and established atherosclerotic CV disease.